Physician profile
Stephen A Lin
NPI 1073612735
$3,356.02
in general payments reported to CMS, 2019-2025
22 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $355 · 2021: $259 · 2022: $92.69 · 2023: $416 · 2024: $557 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $695.47 | 2019-2025 | Clareon, Unity, Hydrus Microstent |
| Allergan, INC. | $437.84 | 2019-2021 | |
| Rxsight INC | $412.12 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $358.81 | 2023-2025 | Miebo, Xiidra, Infuse |
| Oyster Point Pharma, INC. | $257.58 | 2023-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $218.75 | 2019-2020 | |
| Lensar, INC. | $150.43 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $124.99 | 2025 | Acuvue |
| Ivantis, INC | $113.90 | 2020 | |
| Coopervision INC. | $113.02 | 2025 | Misight Contact Lens |
| Eyepoint US, INC. | $103.13 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $81.92 | 2022-2024 | Clarus, Cirrus Hd-Oct |
| Glaukos Corporation | $74.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $39.36 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $33.94 | 2025 | Syfovre |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $29.38 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.44 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $21.32 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $19.74 | 2024 | Xdemvy |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Biotissue Holdings INC. | $14.54 | 2024 | |
| Octapharma USA, INC. | $14.09 | 2025 | Balfaxar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.